The decline comes after the results from its phase 3 trial of CagriSema, its next-generation obesity drug, disappointed investors.
Reacting to the results, analysts at Wolfe Research said: “While we didn't expect CagriSema to be a formidable competitor to Lilly's Zepbound, we now see Lilly in a true class of its own with Zepbound, orforglipron and retatrutide."While MSTR and COIN are up on Friday, +8.1% and +1%, respectively, both names have declined for most of this week. MicroStrategy is down around 14% over the last five days, while Coinbase has declined over 11%.
Australia Australia Latest News, Australia Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Investingcom - 🏆 450. / 53 Read more »